Quick Answer
XORTX Therapeutics Inc. reported R&D Expense of $574.9 thousand for fiscal year 2025.
XORTX Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $574.9K | +212.8% |
| 2024 | $183.8K | -92.4% |
| 2023 | $2.42M | -64.2% |
| 2022 | $6.76M | +897.9% |
| 2021 | $677.6K | +144.2% |
| 2020 | $277.5K | +595.4% |
| 2019 | $39.9K | — |
- XORTX Therapeutics Inc. showed an increase of +212.8% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, XORTX Therapeutics Inc.’s r&d expense has grown by 1341.0% (from $39.9 thousand to $574.9 thousand).
- The most recent figure is from XORTX Therapeutics Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: